Reynaldo Jesus Garcia Filho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reynaldo Jesus Garcia Filho has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jairo Greco Garcia
Universidade Federal de São Paulo, Brazil
6 shared publications - Dan Carai Maia Viola
Universidade Federal de São Paulo, Brazil
5 shared publications - Marcelo DE Toledo Petrilli
Universidade Federal de São Paulo, Brazil
5 shared publications - Caio Falk Giannotti
Universidade Federal de São Paulo, Brazil
3 shared publications - Roberto Carmagnani Pestana
Hospital Israelita Albert Einstein, São Paulo, Brazil
3 shared publications - Douglas Dias e Silva
Hospital Israelita Albert Einstein , São Paulo
2 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 6
Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: a perspective on evidence gaps
- 24 January 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 6
Open AccessPost-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: a perspective on evidence gaps
- Open Access
- 4 January 2026
- Published by Revista Sociedade Científica in Revista Sociedade Científica
- Vol. 9 (1) , 198-228
Benefício clínico e segurança do denosumabe no tumor de células gigantes do osso: revisão sistemática e meta-análise de braço único
O tumor de células gigantes do osso é uma neoplasia osteolítica localmente agressiva na qual o denosumabe se tornou uma opção sistêmica importante, porém ainda há incerteza quanto à durabilidade do controle e à segurança em esquemas do mundo real. Este estudo teve como objetivo sintetizar a efetividade e a segurança do tratamento baseado em denosumabe em pacientes com TCGO com maturidade esquelética. Realizou-se busca nas bases PubMed, EMBASE, Scopus e Cochrane Library estudos clínicos em texto completo e em língua inglesa que avaliaram denosumabe em pacientes com maturidade esquelética e tumor de células gigantes do osso até janeiro de 2026. Os desfechos primários foram benefício clínico e eventos adversos, e os desfechos secundários foram resposta por imagem, recidiva local e falha do tratamento. Uma meta-análise de braço único com modelo de efeitos aleatórios foi realizada, com estabilização de variância e ponderação pelo inverso da variância. A heterogeneidade foi quantificada pelo I², e intervalos preditivos e análises leave-one-out foram utilizados para avaliar a robustez. As análises de subgrupo foram limitadas ao desenho do estudo. Foram analisados 22 estudos, incluindo 1.170 pacientes. A taxa combinada de benefício clínico foi de 79,94% (IC 95% 74,21–85,02; I² 85,8%), e a taxa combinada de resposta por imagem foi de 72,72% (IC 95% 59,46–84,04; I² 97,2%). A recidiva local ocorreu em 24,49% dos pacientes (IC 95% 14,30–36,54; I² 96,5%) e a falha do tratamento em 10,36% (IC 95% 6,74–14,69; I² 57,0%). A taxa combinada de eventos adversos foi de 31,16% (IC 95% 6,76–63,08; I² 98,5%). A análise de subgrupo por desenho do estudo não reduziu de forma consistente a heterogeneidade, os intervalos preditivos foram amplos para a maioria dos desfechos e a meta-regressão utilizando idade média e a proporção de pacientes do sexo feminino não identificou moderadores significativos das estimativas combinadas. Observou-se que o denosumabe esteve associado a benefício clínico significativo e resposta radiológica em pacientes com maturidade esquelética e TCGO, porém, a durabilidade do controle e as estimativas de segurança variaram amplamente entre os estudos, ressaltando a necessidade de desfechos padronizados e de evidência prospectiva comparativa.
- 4 January 2026
- Published by Revista Sociedade Científica in Revista Sociedade Científica
- Vol. 9 (1) , 198-228
Open AccessBenefício clínico e segurança do denosumabe no tumor de células gigantes do osso: revisão sistemática e meta-análise de braço único
O tumor de células gigantes do osso é uma neoplasia osteolítica localmente agressiva na qual o denosumabe se tornou uma opção sistêmica importante, porém ainda há incerteza quanto à durabilidade do controle e à segurança em esquemas do mundo real. Este estudo teve como objetivo sintetizar a efetividade e a segurança do tratamento baseado em denosumabe em pacientes com TCGO com maturidade esquelética. Realizou-se busca nas bases PubMed, EMBASE, Scopus e Cochrane Library estudos clínicos em texto completo e em língua inglesa que avaliaram denosumabe em pacientes com maturidade esquelética e tumor de células gigantes do osso até janeiro de 2026. Os desfechos primários foram benefício clínico e eventos adversos, e os desfechos secundários foram resposta por imagem, recidiva local e falha do tratamento. Uma meta-análise de braço único com modelo de efeitos aleatórios foi realizada, com estabilização de variância e ponderação pelo inverso da variância. A heterogeneidade foi quantificada pelo I², e intervalos preditivos e análises leave-one-out foram utilizados para avaliar a robustez. As análises de subgrupo foram limitadas ao desenho do estudo. Foram analisados 22 estudos, incluindo 1.170 pacientes. A taxa combinada de benefício clínico foi de 79,94% (IC 95% 74,21–85,02; I² 85,8%), e a taxa combinada de resposta por imagem foi de 72,72% (IC 95% 59,46–84,04; I² 97,2%). A recidiva local ocorreu em 24,49% dos pacientes (IC 95% 14,30–36,54; I² 96,5%) e a falha do tratamento em 10,36% (IC 95% 6,74–14,69; I² 57,0%). A taxa combinada de eventos adversos foi de 31,16% (IC 95% 6,76–63,08; I² 98,5%). A análise de subgrupo por desenho do estudo não reduziu de forma consistente a heterogeneidade, os intervalos preditivos foram amplos para a maioria dos desfechos e a meta-regressão utilizando idade média e a proporção de pacientes do sexo feminino não identificou moderadores significativos das estimativas combinadas. Observou-se que o denosumabe esteve associado a benefício clínico significativo e resposta radiológica em pacientes com maturidade esquelética e TCGO, porém, a durabilidade do controle e as estimativas de segurança variaram amplamente entre os estudos, ressaltando a necessidade de desfechos padronizados e de evidência prospectiva comparativa.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 34 (1)
ANEURYSMAL BONE CYST: A CASE SERIES OF AN AGGRESSIVE BENIGN TUMOR
Objective: The Aneurysmal Bone Cyst (ABC) is a benign yet aggressive bone tumor. This study aimed to evaluate sex, age, tumor location, tumor size, type of treatment (surgical, infiltration, embolization), and recurrence. Methods: Descriptive and quantitative statistical analyses were applied. The prevalence ratio and 95% confidence interval were calculated for the association between recurrence and sex, age, tumor size, Capanna's classification, and treatment type. Results: Twenty-three cases of ABCs were included, eleven (47.8%) females and twelve (52.2%) males. The mean age of treated patients was 11.2±1.8 years. Most cysts were located in the lower limbs (56.5%). The mean follow-up time was 42.8±14.01 months. The mean cyst diameter at the beginning of treatment was 5.58± 1.04 cm; of these, 17.4% were up to 3 cm, 43.5% from 3.1 to 6 cm, and 39.1% over 6 cm. Regarding initial treatment, 6 (26%) patients received infiltration, and in total 20 (86.9%) underwent surgery with bone grafting. The overall recurrence rate was 30.4%. No association was identified between recurrence and the variables studied (p ≥ 0.05). The epidemiological data obtained are consistent with pediatric cohorts reported in the literature. Conclusion: All evaluated methods are suitable for treating aneurysmal bone cysts. Level of Evidence IV; Case Series.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 34 (1)
Open AccessANEURYSMAL BONE CYST: A CASE SERIES OF AN AGGRESSIVE BENIGN TUMOR
Objective: The Aneurysmal Bone Cyst (ABC) is a benign yet aggressive bone tumor. This study aimed to evaluate sex, age, tumor location, tumor size, type of treatment (surgical, infiltration, embolization), and recurrence. Methods: Descriptive and quantitative statistical analyses were applied. The prevalence ratio and 95% confidence interval were calculated for the association between recurrence and sex, age, tumor size, Capanna's classification, and treatment type. Results: Twenty-three cases of ABCs were included, eleven (47.8%) females and twelve (52.2%) males. The mean age of treated patients was 11.2±1.8 years. Most cysts were located in the lower limbs (56.5%). The mean follow-up time was 42.8±14.01 months. The mean cyst diameter at the beginning of treatment was 5.58± 1.04 cm; of these, 17.4% were up to 3 cm, 43.5% from 3.1 to 6 cm, and 39.1% over 6 cm. Regarding initial treatment, 6 (26%) patients received infiltration, and in total 20 (86.9%) underwent surgery with bone grafting. The overall recurrence rate was 30.4%. No association was identified between recurrence and the variables studied (p ≥ 0.05). The epidemiological data obtained are consistent with pediatric cohorts reported in the literature. Conclusion: All evaluated methods are suitable for treating aneurysmal bone cysts. Level of Evidence IV; Case Series.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 33 (spe1) , e283605
EPIDEMOLOGICAL, RADIOGRAPHIC AND PROGNOSTIC EVALUATION OF CHONDROBLASTOMA
Objective: To describe the clinical and imaging characteristics of chondroblastoma and identify possible factors related to joint complications.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 33 (spe1) , e283605
Open AccessEPIDEMOLOGICAL, RADIOGRAPHIC AND PROGNOSTIC EVALUATION OF CHONDROBLASTOMA
Objective: To describe the clinical and imaging characteristics of chondroblastoma and identify possible factors related to joint complications.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 33 (1) , e282483
DIAGNOSTIC COMPETENCE IN BONE TUMORS: INFLUENCE OF ONCO-ORTHOPEDIC TRAINING
Understanding the nature of musculoskeletal tumors is crucial for appropriate management and to secure a favorable prognosis. Orthopedists’ ability to identify these pathologies early and accurately is paramount. There is a requirement to raise awareness within the orthopedic community regarding the necessity of referrals to orthopedic oncology specialists, as delays in initiating proper treatment can compromise patient prognosis. Objective: The objective was to assess the capability of non-specialist orthopedists in identifying bone lesions suggestive of tumors and thus classify them by employing a questionnaire with radiographs and comparison with specialists. We aim to gain an in-depth understanding of their diagnostic competence and provide insights into teaching the subject in orthopedic residency programs. Methods: The sample consisted of 90 participants who answered the questionnaire: 18 orthopedic oncology specialists, 58 non-specialist orthopedists, and 14 orthopedic residents. Results: Specialists achieved an average accuracy of 12.50 ± 1.07, while non-specialists scored 10.00 ± 0.60 (p<0.001). Among non-specialists, there was no statistical significance when comparing whether they underwent specialization internship during residency nor the duration of the year of such training. The period since graduation also indicated no differences. Conclusion: This study highlights the importance of referring patients with suspected tumors to specialized orthopedists. Level of Evidence V; Expert Opinion.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 33 (1) , e282483
Open AccessDIAGNOSTIC COMPETENCE IN BONE TUMORS: INFLUENCE OF ONCO-ORTHOPEDIC TRAINING
Understanding the nature of musculoskeletal tumors is crucial for appropriate management and to secure a favorable prognosis. Orthopedists’ ability to identify these pathologies early and accurately is paramount. There is a requirement to raise awareness within the orthopedic community regarding the necessity of referrals to orthopedic oncology specialists, as delays in initiating proper treatment can compromise patient prognosis. Objective: The objective was to assess the capability of non-specialist orthopedists in identifying bone lesions suggestive of tumors and thus classify them by employing a questionnaire with radiographs and comparison with specialists. We aim to gain an in-depth understanding of their diagnostic competence and provide insights into teaching the subject in orthopedic residency programs. Methods: The sample consisted of 90 participants who answered the questionnaire: 18 orthopedic oncology specialists, 58 non-specialist orthopedists, and 14 orthopedic residents. Results: Specialists achieved an average accuracy of 12.50 ± 1.07, while non-specialists scored 10.00 ± 0.60 (p<0.001). Among non-specialists, there was no statistical significance when comparing whether they underwent specialization internship during residency nor the duration of the year of such training. The period since graduation also indicated no differences. Conclusion: This study highlights the importance of referring patients with suspected tumors to specialized orthopedists. Level of Evidence V; Expert Opinion.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400239
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group
PURPOSE: The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world. METHODS: In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals. RESULTS: The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively. CONCLUSION: Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400239
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group
PURPOSE: The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world. METHODS: In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals. RESULTS: The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively. CONCLUSION: Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.
- Open Access
- 26 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eRC1107
Beyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib
Pseudomyogenic hemangioendothelioma is an ultra-rare vascular sarcoma that most commonly affects young adults, with a male predominance. It is diagnosed using a combination of imaging studies, histopathological examinations, and immunohistochemical staining. Surgical excision is the mainstay of treatment for pseudomyogenic hemangioendothelioma, with the goal of achieving a wide local excision and reducing the risk of recurrence. The role of systemic therapies is not well established because of the rarity of pseudomyogenic hemangioendothelioma, uncertainty regarding its response to currently approved
- 26 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eRC1107
Open AccessBeyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib
Pseudomyogenic hemangioendothelioma is an ultra-rare vascular sarcoma that most commonly affects young adults, with a male predominance. It is diagnosed using a combination of imaging studies, histopathological examinations, and immunohistochemical staining. Surgical excision is the mainstay of treatment for pseudomyogenic hemangioendothelioma, with the goal of achieving a wide local excision and reducing the risk of recurrence. The role of systemic therapies is not well established because of the rarity of pseudomyogenic hemangioendothelioma, uncertainty regarding its response to currently approved
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 32 (3) , e289310
ELIO CONSENTINO: 04/16/1937 - 08/02/2024
Dr. Elio Consentino, one of the pioneers of Orthopedic Oncology in our country and a mentor to a generation of orthopedists in Brazil and Latin America, passed away on August 2.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 32 (3) , e289310
Open AccessELIO CONSENTINO: 04/16/1937 - 08/02/2024
Dr. Elio Consentino, one of the pioneers of Orthopedic Oncology in our country and a mentor to a generation of orthopedists in Brazil and Latin America, passed away on August 2.
- Open Access
- 4 August 2023
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 33 (2) , 185-190
Biópsía Percutânea nas Lesões Neoplásicas do Esqueleto
O autor discute novos conceitos a respeito das biópsias ósseas. Propõe a utilização das biópsias percutâneas nas lesões neoplásicas primárias ou secundárias do esqueleto. Apresenta a técnica do método fechado através de agulhas de diferentes calibres e formas, em 209 pacientes, em regime ambulatorial e sob controle radiográfico. O método mostrou-se seguro, econômico e relativamente indolor, fornecendo amostras de tecido suficientes para o diagnóstico histológico, citológico e bacterioscópico, com uma precisão de 85%. O método não impede a realização posterior de biópsias abertas e contribuiu sobremaneira para aumentaras indicações de cirurgias conservadoras que evitam a amputação.
- 4 August 2023
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 33 (2) , 185-190
Open AccessBiópsía Percutânea nas Lesões Neoplásicas do Esqueleto
O autor discute novos conceitos a respeito das biópsias ósseas. Propõe a utilização das biópsias percutâneas nas lesões neoplásicas primárias ou secundárias do esqueleto. Apresenta a técnica do método fechado através de agulhas de diferentes calibres e formas, em 209 pacientes, em regime ambulatorial e sob controle radiográfico. O método mostrou-se seguro, econômico e relativamente indolor, fornecendo amostras de tecido suficientes para o diagnóstico histológico, citológico e bacterioscópico, com uma precisão de 85%. O método não impede a realização posterior de biópsias abertas e contribuiu sobremaneira para aumentaras indicações de cirurgias conservadoras que evitam a amputação.
- Open Access
- 4 August 2023
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 33 (2) , 127-132
A importância do Estadiamento do Planejamento Cirúrgico dos Tumores Músculo-esqueléticos
O autor propõe uma classificação e estadiamento baseados na classificação internacional, para o estadiamento dos tumores do sistema músculo-esquelético. Com base em critérios clínicos, radiológicos e histológicos (G); localização (T) e presença ou ausência de metástases (M), descreve os estágios progressivos, o que auxilia na definição do melhor tratamento cirúrgico e no prognóstico. O sistema é viável em nosso meio e serve como um guia útil na seleção do melhor tratamento cirúrgico. Sua utilização permite estudos comparativos dos resultados no que diz respeito aos métodos cirúrgicos e não-cirúrgicos de tratamento.
- 4 August 2023
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 33 (2) , 127-132
Open AccessA importância do Estadiamento do Planejamento Cirúrgico dos Tumores Músculo-esqueléticos
O autor propõe uma classificação e estadiamento baseados na classificação internacional, para o estadiamento dos tumores do sistema músculo-esquelético. Com base em critérios clínicos, radiológicos e histológicos (G); localização (T) e presença ou ausência de metástases (M), descreve os estágios progressivos, o que auxilia na definição do melhor tratamento cirúrgico e no prognóstico. O sistema é viável em nosso meio e serve como um guia útil na seleção do melhor tratamento cirúrgico. Sua utilização permite estudos comparativos dos resultados no que diz respeito aos métodos cirúrgicos e não-cirúrgicos de tratamento.